Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro.

Area of Science:

• Immunology
• Molecular Biology
• Biochemistry

Background:

• Patients with hemophilia A receiving therapeutic factor VIII (FVIII) can develop inhibitory anti-FVIII IgG antibodies.
• Antigen-presenting cell (APC) maturation and co-stimulation are crucial for initiating antigen-specific immune responses.
• The danger signals that induce APC maturation and anti-FVIII immune responses are not well understood, with conflicting reports on FVIII's direct effect on APCs.

Purpose of the Study:

• To investigate whether therapeutic factor VIII (FVIII) directly triggers Toll-like receptor 2 (TLR2) signaling.
• To determine if FVIII promotes the maturation of antigen-presenting cells (APCs).

Main Methods:

• Flow cytometry was used to assess the maturation of mouse bone marrow-derived macrophages (BMAs) treated with human recombinant FVIII.
• HEK293 cells transfected with reporter constructs for NFκB activity were used to analyze TLR1/2 or TLR2/6 signaling triggered by FVIII.
• Zymosan, a known TLR2 agonist, served as a positive control.

Main Results:

• Human recombinant FVIII did not induce maturation of mouse BMA macrophages, as indicated by unchanged surface expression of CD80, CD86, CD40, and I-Ab.
• FVIII failed to activate NFκB in HEK293 cells expressing TLR2 with TLR1 or TLR6, unlike zymosan which triggered NFκB activity.
• These findings indicate FVIII alone does not directly activate TLR2 signaling pathways.

Conclusions:

• Therapeutic factor VIII (FVIII) alone is insufficient to trigger antigen-presenting cell (APC) maturation via Toll-like receptor 2 (TLR2) signaling.
• The study provides evidence against a direct role of FVIII in initiating the immune response through TLR2 activation.
• Further research is needed to elucidate the precise mechanisms underlying anti-FVIII immune responses in hemophilia A patients.